Thioridazine HCl, no NHI reimbursable from coming July.
Published: 2005-04-26 06:58:00
Updated: 2005-04-26 06:58:00
As of July 1, the product registration of Thioridazine preparations (anti-psychotic drug) will be cancelled according to the KFDA and therefore its NHI reimbursement shall be also suspended, the Health Insurance Review Agency (HIRA) said.
Th KFDA said that the NHI reimbursed 6 brands of Thiori...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
